Difference between revisions of "Sutimlimab (Enjaymo)"
Jump to navigation
Jump to search
m |
|||
| Line 7: | Line 7: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*2/4/2022: Approved to decrease the need for red blood cell transfusion due to hemolysis (red blood cell destruction) in adults with [[Cold agglutinin disease|cold agglutinin disease (CAD)]]. ''(Based on CARDINAL)'' | *2/4/2022: Approved to decrease the need for red blood cell transfusion due to hemolysis (red blood cell destruction) in adults with [[Cold agglutinin disease|cold agglutinin disease (CAD)]]. ''(Based on CARDINAL)'' | ||
| − | + | ==History of changes in EMA indication== | |
| + | *11/15/2022: Initial authorization | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' BIVV009 | *'''Code name:''' BIVV009 | ||
| Line 19: | Line 20: | ||
[[Category:Cold agglutinin disease medications]] | [[Category:Cold agglutinin disease medications]] | ||
| + | [[Category:EMA approved in 2022]] | ||
[[Category:FDA approved in 2022]] | [[Category:FDA approved in 2022]] | ||
Revision as of 13:25, 31 December 2022
Mechanism of action
Anti-C1s antibody
Diseases for which it is used
History of changes in FDA indication
- 2/4/2022: Approved to decrease the need for red blood cell transfusion due to hemolysis (red blood cell destruction) in adults with cold agglutinin disease (CAD). (Based on CARDINAL)
History of changes in EMA indication
- 11/15/2022: Initial authorization
Also known as
- Code name: BIVV009
- Generic name: sutimlimab-jome
- Brand name: Enjaymo